INDEPENDENT THINKING. TRACEABLE EVIDENCE.Research edition · 29 October 2026
Modern DosingTHE PRACTITIONER’S PERSPECTIVEA clearer view of
the peptide economy ↗
The provider file / Dossier 248
RESEARCH DOSSIER / NOT AN ENDORSEMENT

Omada Health

A dated business research record, with the original field-level evidence labels kept intact.

Source snapshot: 2026-10-29. “Verified” below is the source dataset author’s label—not an independent license, safety, quality or clinical audit by Modern Dosing. These pages are excluded from search indexing until reviewed.
Positioning & service claimsverified

Employer GLP-1 strategy across covered and cash-pay benefits, with lifestyle support and guided medication care.

Audienceread

Our read: Employer GLP-1 strategy across covered and cash-pay benefits, with lifestyle support and guided medication care.

Pricing & termspartial

Custom employer/plan contract; no universal drug or program fee.

Clinical relationshipspartial

Wheel prescribing partner; Omada coaches/care team provide between-visit support.

Pharmacy & fulfillmentpartial

PBM/coverage or cash-pay routes; no universal named dispensing pharmacy.

Advertising snapshotsnapshot

Channel-specific public-library evidence below; counts are observations, never spend/performance.

Founding yearverified

2011

Founderspartial

Sean Duffy and Adrian James named in IDEO origin story. Complete founder roster not established.

Location & entity contextverified

South San Francisco, California, principal executive offices per 2025 annual report.

Search visibility samplesnapshot

Public first-party program page found and read. Rankings, traffic, index totals and authority not measured.

THE MODERN DOSING WEEKLY

The peptide news
that changes your week.

Evidence-backed developments. The moves that matter. What each means for your practice or business—in one weekly email.